Breast Cancer Clinical Trial
Official title:
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase
Verified date | August 2023 |
Source | Syndax Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC). Additionally, the purpose of the study is to assess how effective entinostat and atezolizumab are in combination in participants with aTNBC.
Status | Completed |
Enrollment | 89 |
Est. completion date | March 10, 2021 |
Est. primary completion date | March 10, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Has histologically or cytologically confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment. 2. Evidence of measurable, locally recurrent or metastatic disease based on imaging studies within 28 days before the first dose of study drug. 3. Has received at least 1, but no more than 2, prior lines of systemic therapy for locally recurrent and/or metastatic disease. 4. If participant has a history of treated asymptomatic CNS metastases they are eligible, provided they meet all of the following criteria: participant has measurable disease outside CNS; participant does not have metastases to midbrain, pons, medulla or spinal cord; participant is not on corticosteroids as therapy for CNS disease (anticonvulsants at a stable dose are allowed); participant has not had whole-brain radiation within 6 weeks prior to study enrollment; participant has stable CNS disease as demonstrated by at least 4 weeks of stability between the last intervention scan and the study screening scan. 5. ECOG performance status of 0 or 1. 6. Has acceptable, applicable laboratory parameters. 7. Female participants must not be pregnant; willing to use 2 methods of birth control/abstinence if applicable through 120 days after the last dose of study drug. 8. Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade <1 (except alopecia or neuropathy). 9. Able to understand and give written informed consent and comply with study procedures. Exclusion Criteria: 1. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. 2. Active autoimmune disease including active diverticulitis, symptomatic peptic ulcer disease, colitis, or inflammatory bowel disease that has required systemic treatment in past 2 years. 3. Previously treated with a PD-1/PD-L1-blocking antibody or a histone deacetylase inhibitor. 4. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator, including, but not limited to: history of immune deficiencies or autoimmune disease; myocardial infarction or arterial thromboembolic events within 6 months prior to screening or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval > 470 msec; uncontrolled hypertension or diabetes mellitus; another known malignancy that is progressing or requires active treatment; active infection requiring systemic therapy; known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 5. Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption. 6. Received a live vaccine within 30 days of the first dose of treatment. 7. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to enrollment or who has not recovered from AEs due to mAb agents administered more than 4 weeks earlier. 8. Prior chemotherapy within 3 weeks, targeted small molecule therapy or radiation therapy within 2 weeks prior to enrollment, or who has not recovered (i.e., =Grade 1 at enrollment) from AEs due to a previously administered agent. 9. Received transfusion of blood products or administration of colony stimulating factors within 4 weeks prior to the first dose of treatment. 10. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug. 11. Currently receiving treatment with any other agent listed on the prohibited medication list. 12. If female, is pregnant, breastfeeding, or expecting to conceive starting with the screening visit through 120 days after the last dose of study drug. 13. Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). 14. Known active hepatitis B or hepatitis C. 15. Allergy to benzamide or inactive components of entinostat. 16. History of allergies to any active or inactive ingredients of atezolizumab. 17. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. |
Country | Name | City | State |
---|---|---|---|
Georgia | Cancer Center of Adjara Autonomous Republic | Batumi | Adjara |
Georgia | Saint Nikolozi Surgery and Oncological Centre | Kutaisi | Imereti |
Georgia | Unimed Adjara - Oncology Center | Kutaisi | Imereti |
Georgia | Cancer Research Center | Tbilisi | |
Georgia | Health House | Tbilisi | |
Georgia | Institute of Clinical Oncology | Tbilisi | |
Georgia | Multiprofile Clinic Consilium Medulla | Tbilisi | |
Georgia | New Vision University Hospital | Tbilisi | |
Georgia | Research Institute of Clinical Medicine | Tbilisi | |
Georgia | S. Khechinashvili, University Hospital | Tbilisi | |
United States | Hope Women's Cancer Centers | Asheville | North Carolina |
United States | CBCC Global Research at Comprehensive Blood and Cancer Center | Bakersfield | California |
United States | UAB Comprehensive Cancer Center | Birmingham | Alabama |
United States | Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas |
United States | Ft. Wayne Hematology and Oncology | Fort Wayne | Indiana |
United States | Ft. Wayne Medical Oncology & Hematology, Inc | Fort Wayne | Indiana |
United States | St. Jude Medical Center | Fullerton | California |
United States | Los Angeles Hematology Oncology Medical Group | Glendale | California |
United States | Saint Mary's Regional Cancer Center | Grand Junction | Colorado |
United States | Office of Human Research | Hollywood | Florida |
United States | Saint Barnabas Medical Cancer Center | Livingston | New Jersey |
United States | Orlando Health, Inc. | Orlando | Florida |
United States | Torrance Memorial Cancer Care Associates | Redondo Beach | California |
United States | Frauenshuh Cancer Center at Park Nicollet Health Service | Saint Louis Park | Minnesota |
United States | SLO Oncology and Hematology Health Center | San Luis Obispo | California |
United States | Central Coast Medical Oncology Group | Santa Maria | California |
United States | UCLA Hematology/Oncology - Santa Monica | Santa Monica | California |
United States | Cancer Center of Kansas | Wichita | Kansas |
United States | Wake Forest Baptist Medical Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Syndax Pharmaceuticals | Roche Pharma AG |
United States, Georgia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1b: Participants Experiencing DLT | Phase 1b employed a classical 3+3 design, with the determination of DLT based on entinostat in combination with atezolizumab within the first cycle of treatment (that is, between Day 1 to Day 21 of Cycle 1). Six participants were required to be treated in a dose level for it to be considered MTD or the Recommended Phase 2 Dose (RP2D). A DLT was defined as the occurrence of specific events, defined in the protocol, that were considered by the investigator to be at least possibly related to study drug using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.03.The DLT assessment window (Cycle 1) was the time period between Cycle 1 Day 1 until Cycle 2 Day 1 (expected to be 21 days after Cycle 1 Day 1). | Up to 21 days after Cycle 1 Day 1 | |
Primary | Phase 1b: Determination of the RP2D | Phase 1b employed a classical 3+3 design, with the determination of the RP2D based on entinostat in combination with atezolizumab within the first cycle of treatment (that is, between Day 1 to Day 21 of Cycle 1). The RP2D was defined as equal to or less than the preliminary maximum tolerated dose (MTD) and was determined in discussion with the sponsor, the study medical monitor, and dose determination phase investigators. The MTD was defined as the highest dose level at which <33% of 6 participants experience DLT. | Up to 21 days after Cycle 1 Day 1 | |
Primary | Phase 2 Expansion: Duration of Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | The duration of PFS, assessed using RECIST 1.1, was used to evaluate the efficacy of entinostat at the RP2D in combination with atezolizumab in participants with advanced triple negative breast cancer (aTNBC). It was defined as the number of months from randomization to the earlier of progressive disease or death due to any cause. One month was considered 30.4375 days. PFS (months) = (Date of Progression or Censoring - Date of Randomization + 1)/30.4375. | Up to 1 year | |
Secondary | Phase 2 Expansion: Duration of PFS Using Immune Response RECIST (irRECIST) | The duration of PFS, assessed using irRECIST, was used to evaluate the efficacy of entinostat at the RP2D in combination with atezolizumab in participants with aTNBC. It was defined as the number of months from randomization to the earlier of progressive disease or death due to any cause. One month was considered 30.4375 days. PFS (months) = (Date of Progression or Censoring - Date of Randomization + 1)/30.4375. | Up to 1 year | |
Secondary | Phase 2 Expansion: Overall Response Rate (ORR) Using RECIST 1.1 and irRECIST | ORR was defined as the crude percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) assessed using RECIST 1.1 and irRECIST. ORR calculated as: (number of participants with best overall response as CR or PR)/total number of participants. The overall response was determined locally by the investigator at each scheduled assessment. | Up to 1 year | |
Secondary | Phase 2 Expansion: Clinical Benefit Rate (CBR) Using RECIST 1.1 and irRECIST | CBR was estimated based on the crude percentage of participants in each treatment arm whose best overall response during the course of study treatment was CR, PR, or stable disease (SD) lasting for at least 24 weeks (measured from the date of randomization to the last date where SD was reported). | Up to 1 year | |
Secondary | Phase 2 Expansion: Overall Survival (OS) | OS was defined as the number of months from randomization to date of death from any cause. Participants who were alive or lost to follow-up as of a data analysis cutoff date were right-censored. One month was considered 30.4375 days. OS (months) = (Date of Death/Censoring - Date of Randomization + 1)/30.4375 | Up to 5 years | |
Secondary | Phase 2 Expansion: Duration of Response (DOR) | DOR was defined as the number of months from the date where a CR/PR (based on RECIST 1.1) or immune response CR (irCR)/immune response PR (irPR) was firstly observed, to the first date that recurrent or progressive disease was documented. | Up to 2 years | |
Secondary | Phase 2 Expansion: Time To Response (TTR) | TTR was defined for the subset of participants that achieved best overall response of confirmed CR/PR or confirmed irCR/irPR as the number of months from date of randomization to date of the initial documented response of CR/PR (based on RECIST 1.1) or irCR/irPR (based on irRECIST). | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |